AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27807908 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based management (discharge after 2 days for home-based management with nurse visits and multi-disciplinary team visits)
Number of subjects: 50
Study 27807908 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based management
Number of subjects: 50
Study 27807908 — intervention group
Group type: COMPARATOR
Intervention: Inpatient care (standard care with a 5 to 6 day initial inpatient stay)
Number of subjects: 50
Study 25201130 — intervention group
Group type: EXPERIMENTAL
Intervention: Belly dancing (RG)
Number of subjects: 114
Study 25201130 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care (CG)
Number of subjects: 114
Study 23403883 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dose (20 mg iron and 100 μg folic acid)
Number of subjects: 426
Study 23403883 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dose doubled (40 mg iron and 200 μg folic acid)
Number of subjects: 426
Study 23403883 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly dose (40 mg iron and 200 μg folic acid)
Number of subjects: 426
Study 20963434 — intervention group
Group type: EXPERIMENTAL
Intervention: BG-12 (240 mg orally three times daily for 24 weeks)
Number of subjects: 56
Study 20963434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 20963434 — intervention group
Group type: EXPERIMENTAL
Intervention: BG-12
Number of subjects: 56
Study 19597913 — intervention group
Group type: EXPERIMENTAL
Intervention: diacerein
Number of subjects: 64
Study 19597913 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 64
Study 16714913 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-week applied relaxation training sessions
Number of subjects: 110
Study 16714913 — intervention group
Group type: COMPARATOR
Intervention: Routine prenatal care
Number of subjects: 110
Study 14992663 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-initiated discussions of substance use and increased anxiety during family interactions (African American patients)
Number of subjects: 58
Study 14992663 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of odd thinking and parents' criticism (White patients)
Number of subjects: 58
Study 14992663 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression during interaction (White patients)
Number of subjects: 58
Study 11161392 — intervention group
Group type: EXPERIMENTAL
Intervention: Third generation chemotherapy regimens
Number of subjects: 1982
Study 11161392 — intervention group
Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 1982
Study 9237707 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha treatment
Number of subjects: 62
Study 9237707 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 62
Study 7957488 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK8
Number of subjects: 0
Study 7957488 — intervention group
Group type: EXPERIMENTAL
Intervention: G17
Number of subjects: 0
Study 7957488 — intervention group
Group type: COMPARATOR
Intervention: Loxiglumide
Number of subjects: 0
Study 7957488 — intervention group
Group type: COMPARATOR
Intervention: Post-prandial condition
Number of subjects: 0
Study 2890546 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine 300 mg immediately after dinner
Number of subjects: 7
Study 2890546 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine 300 mg 3 hours after dinner
Number of subjects: 7
Study 2890546 — intervention group
Group type: EXPERIMENTAL
Intervention: famotidine 40 mg immediately after dinner
Number of subjects: 7
Study 2890546 — intervention group
Group type: EXPERIMENTAL
Intervention: famotidine 40 mg 3 hours after dinner
Number of subjects: 7
Study 2890546 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7
Study 30584220 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate (400 mg/day)
Number of subjects: 66
Study 30584220 — intervention group
Group type: COMPARATOR
Intervention: Eicosapentaenoic acid (EPA 1.8 g/day)
Number of subjects: 66
Study 29126691 — intervention group
Group type: EXPERIMENTAL
Intervention: tranexamic acid 10mg/kg body weight
Number of subjects: 80
Study 29126691 — intervention group
Group type: EXPERIMENTAL
Intervention: tranexamic acid 15mg/kg body weight
Number of subjects: 80
Study 29126691 — intervention group
Group type: EXPERIMENTAL
Intervention: tranexamic acid 20mg/kg body weight
Number of subjects: 80
Study 29126691 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 80
Study 25668386 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based delivery of motivational interviewing plus skills building for 3 months
Number of subjects: 181
Study 25668386 — intervention group
Group type: COMPARATOR
Intervention: Office-based delivery of motivational interviewing plus skills building for 3 months
Number of subjects: 181
Study 25668386 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued home-based skills for nonresponders after 3 months
Number of subjects: 181
Study 25668386 — intervention group
Group type: COMPARATOR
Intervention: Contingency management for nonresponders after 3 months
Number of subjects: 181
Study 25668386 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment effect
Number of subjects: 181
Study 25668386 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent executive functioning
Number of subjects: 181
Study 25452097 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined music and aroma
Number of subjects: 224
Study 25452097 — intervention group
Group type: EXPERIMENTAL
Intervention: Music alone
Number of subjects: 224
Study 25452097 — intervention group
Group type: EXPERIMENTAL
Intervention: Aroma alone
Number of subjects: 224
Study 25452097 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 224
Study 22289131 — intervention group
Group type: EXPERIMENTAL
Intervention: Drink refusal skills training (part of a 16-week combined behavioral intervention)
Number of subjects: 776
Study 20574136 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate (200-400 mg/day)
Number of subjects: 274
Study 20574136 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (10-20 mg/day)
Number of subjects: 274
Study 17640111 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 500 microg once daily
Number of subjects: 1514
Study 17640111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1514
Study 17640111 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 500 microg once daily (in subgroup of very severe COPD)
Number of subjects: 1514
Study 17640111 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in subgroup of very severe COPD)
Number of subjects: 1514
Study 17640111 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 500 microg once daily (in subgroup of high healthcare utilization)
Number of subjects: 1514
Study 17640111 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in subgroup of high healthcare utilization)
Number of subjects: 1514
Study 16103242 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric analysis technique using RT3DE images
Number of subjects: 30
Study 16103242 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated detection of regional WM abnormalities
Number of subjects: 30
Study 11815511 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 12
Study 11815511 — intervention group
Group type: COMPARATOR
Intervention: Dipyridamole
Number of subjects: 12
Study 10412677 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster schedule
Number of subjects: 63
Study 10412677 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional schedule
Number of subjects: 63
Study 10412677 — intervention group
Group type: COMPARATOR
Intervention: Control group (no immunotherapy)
Number of subjects: 63
Study 7749804 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (24% fat)
Number of subjects: 103
Study 7749804 — intervention group
Group type: COMPARATOR
Intervention: High-fat diet (46% fat)
Number of subjects: 103
Study 2331203 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol screening with brief nonphysician counseling (3- to 5-minute counseling by a registered nurse)
Number of subjects: 886
Study 2331203 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent follow-up (cholesterol measurement and brief counseling at 2, 4, and 6 months)
Number of subjects: 886
Study 2331203 — intervention group
Group type: COMPARATOR
Intervention: Follow-up at 6 months only
Number of subjects: 886
Study 373260 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1000 mg daily for 4 weeks
Number of subjects: 91
Study 373260 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 91
Study 31430404 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW-CHO
Number of subjects: 13
Study 31430404 — intervention group
Group type: COMPARATOR
Intervention: HIGH-CHO
Number of subjects: 13
Study 26193827 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led structured psychosocial intervention program (plus usual care)
Number of subjects: 180
Study 26193827 — intervention group
Group type: COMPARATOR
Intervention: Usual psychiatric outpatient care
Number of subjects: 180
Study 23784892 — intervention group
Group type: EXPERIMENTAL
Intervention: four‐session lifestyle program
Number of subjects: 228
Study 21130987 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracytoplasmic morphologically selected sperm injection (IMSI)
Number of subjects: 120
Study 21130987 — intervention group
Group type: COMPARATOR
Intervention: Intracytoplasmic sperm injection (ICSI)
Number of subjects: 120
Study 19299766 — intervention group
Group type: EXPERIMENTAL
Intervention: Air/Oxygen (FIO2 = 0.4)
Number of subjects: 100
Study 19299766 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide/Oxygen (N2O, FIO2 = 0.4)
Number of subjects: 100
Study 19299766 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen (O2, FIO2 = 1.0)
Number of subjects: 100
Study 17855668 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilute diesel exhaust (300 mug per cubic meter)
Number of subjects: 20
Study 17855668 — intervention group
Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 20
Study 17855668 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilute diesel exhaust
Number of subjects: 20
Study 15184734 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 7601
Study 11482588 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Care Financing Administration's pilot Medicare & You 1999 handbook
Number of subjects: 2000
Study 11482588 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicare version of the Consumer Assessment of Health Plans (CAHPS) report
Number of subjects: 2000
Study 11482588 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicare & You bulletin, an abbreviated version of the handbook
Number of subjects: 2000
Study 11482588 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2000
Study 9726084 — intervention group
Group type: EXPERIMENTAL
Intervention: Safer-sex education (individual teaching approach)
Number of subjects: 0
Study 9726084 — intervention group
Group type: EXPERIMENTAL
Intervention: Safer-sex education (interactive education methods)
Number of subjects: 0
Study 7913703 — intervention group
Group type: EXPERIMENTAL
Intervention: p105 labeling index (LI-C)
Number of subjects: 143
Study 7913703 — intervention group
Group type: EXPERIMENTAL
Intervention: p105 labeling index of cells in S phase (LI-S)
Number of subjects: 143
Study 7913703 — intervention group
Group type: EXPERIMENTAL
Intervention: p105 antigen density (AD)
Number of subjects: 143
Study 7913703 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA ploidy
Number of subjects: 143
Study 7913703 — intervention group
Group type: EXPERIMENTAL
Intervention: T-stage
Number of subjects: 143
Study 7913703 — intervention group
Group type: EXPERIMENTAL
Intervention: N-stage
Number of subjects: 143
Study 7913703 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary site
Number of subjects: 143
Study 2729315 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide 5 mg
Number of subjects: 10
Study 2729315 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide + Albuterol
Number of subjects: 10
Study 2729315 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide + Albuterol (Women)
Number of subjects: 10
Study 2729315 — intervention group
Group type: COMPARATOR
Intervention: Albuterol alone
Number of subjects: 10
Study 2729315 — intervention group
Group type: COMPARATOR
Intervention: Albuterol
Number of subjects: 10
Study 31164116 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental anhydrous 0.454% SnF2/polyphosphate toothpaste (Test)
Number of subjects: 0
Study 31164116 — intervention group
Group type: COMPARATOR
Intervention: 0.76% sodium monofluorophosphate toothpaste (Control)
Number of subjects: 0
Study 29096915 — intervention group
Group type: COMPARATOR
Intervention: Provisional Stenting (PS), n = 242
Number of subjects: 482
Study 29096915 — intervention group
Group type: EXPERIMENTAL
Intervention: Double Kissing (DK) crush stenting, n = 240
Number of subjects: 482
Study 29096915 — intervention group
Group type: COMPARATOR
Intervention: Provisional Stenting (PS)
Number of subjects: 482
Study 29096915 — intervention group
Group type: EXPERIMENTAL
Intervention: Double Kissing (DK) crush stenting
Number of subjects: 482
Study 26512046 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron, aprepitant, and dexamethasone (RAD)
Number of subjects: 299
Study 26512046 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron, aprepitant, and dexamethasone (OAD)
Number of subjects: 299
Study 23391465 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA85A
Number of subjects: 2797
Study 23391465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2797
Study 21256000 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with cisplatin plus 5‐fluorouracil (5‐FU) and intravenous ZOL (4 mg, q4 wks) for 3 months
Number of subjects: 60
Study 21256000 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy with cisplatin plus 5‐fluorouracil (5‐FU) alone
Number of subjects: 60
Study 18067561 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial thrombosuction (IT)
Number of subjects: 74
Study 18067561 — intervention group
Group type: COMPARATOR
Intervention: Standard PCI
Number of subjects: 74
Study 18067561 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial thrombosuction (IT) in subgroup 2 (241-480 min)
Number of subjects: 74
Study 18067561 — intervention group
Group type: COMPARATOR
Intervention: Standard PCI in subgroup 2 (241-480 min)
Number of subjects: 74
Study 16564942 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vitamin C (300 mg with each dialysis session)
Number of subjects: 46
Study 16564942 — intervention group
Group type: COMPARATOR
Intervention: Standard care only (Control group)
Number of subjects: 46
Study 12629463 — intervention group
Group type: COMPARATOR
Intervention: 3 weeks of bicycle ergometer training, 45 min of exercise at 70% VO(2)max, 3‐4 times a week
Number of subjects: 12
Study 12629463 — intervention group
Group type: COMPARATOR
Intervention: 3 weeks of bicycle ergometer training
Number of subjects: 12
Study 11145380 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate
Number of subjects: 50
Study 8884050 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smokers with occupational exposure to organic solvents
Number of subjects: 139
Study 8884050 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-smokers with occupational exposure to organic solvents
Number of subjects: 139
Study 8884050 — intervention group
Group type: COMPARATOR
Intervention: Smokers not exposed to chemical compounds
Number of subjects: 139
Study 8884050 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers not exposed to chemical compounds
Number of subjects: 139
Study 1733001 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 0
Study 1733001 — intervention group
Group type: COMPARATOR
Intervention: Other medications used commonly for secondary prophylaxis
Number of subjects: 0
Study 6704282 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (single sublingual dose)
Number of subjects: 8
Study 6704282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31416472 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise in heat (30°C)
Number of subjects: 18
Study 31416472 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise in cold (-10°C)
Number of subjects: 18
Study 31416472 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise in temperate (21°C)
Number of subjects: 18
Study 31416472 — intervention group
Group type: COMPARATOR
Intervention: Resting (sedentary) at 21°C
Number of subjects: 18
Study 31416472 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment period (6h after treatment)
Number of subjects: 18
Study 29960852 — intervention group
Group type: EXPERIMENTAL
Intervention: KetoCal® (4:1 ketogenic ratio formula), 8-ounce (237 mL) daily for the first month
Number of subjects: 80
Study 29960852 — intervention group
Group type: COMPARATOR
Intervention: Modified Atkins Diet (MAD) alone
Number of subjects: 80
Study 26682757 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine
Number of subjects: 498
Study 25375851 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspheric LASIK
Number of subjects: 40
Study 25375851 — intervention group
Group type: COMPARATOR
Intervention: Wavefront-guided LASIK
Number of subjects: 40
Study 21465608 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional curvilinear transducer and MTI filtered color flow mapping
Number of subjects: 300
Study 21465608 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency linear transducer
Number of subjects: 300
Study 21465608 — intervention group
Group type: EXPERIMENTAL
Intervention: MTI filtered color flow mapping
Number of subjects: 300
Study 20188444 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin 6 mg/kg/day
Number of subjects: 53
Study 20188444 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (vancomycin 1g every 12h or antistaphylococcal penicillin 2g every 4h, both with gentamicin 1mg/kg every 8h for the first 4 days)
Number of subjects: 53
Study 20188444 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 53
Study 17659004 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg oral Polypodium leucotomos three times daily with NB-UVB twice weekly
Number of subjects: 50
Study 17659004 — intervention group
Group type: COMPARATOR
Intervention: Placebo with NB-UVB twice weekly
Number of subjects: 50
Study 16195287 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol 600 microg
Number of subjects: 661
Study 16195287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 661
Study 12124820 — intervention group
Group type: EXPERIMENTAL
Intervention: CMFEV (cyclophosphamide, methotrexate, epirubicin, and vincristine)
Number of subjects: 211
Study 12124820 — intervention group
Group type: COMPARATOR
Intervention: CMF (cyclophosphamide, methotrexate, and 5-fluorouracil)
Number of subjects: 211
Study 11040233 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat (ACE inhibitor)
Number of subjects: 48
Study 11040233 — intervention group
Group type: COMPARATOR
Intervention: Dihydralazine (nonspecific vasodilator)
Number of subjects: 48
Study 8615488 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimenhydrinate 0.5 mg/kg intravenously
Number of subjects: 80
Study 8615488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 1580727 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin therapy
Number of subjects: 1214
Study 6146006 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir 200 mg four times a day
Number of subjects: 56
Study 6146006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 30640697 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous oxaliplatin 75 mg/m2 on day 1 and intraperitoneal docetaxel 75 mg/m2 on day 2
Number of subjects: 12
Study 30184035 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Inspiratory Muscle Training (IMT) associated with aerobic exercise
Number of subjects: 24
Study 30184035 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise only (Control)
Number of subjects: 24
Study 27812501 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture plus fluoxetine
Number of subjects: 46
Study 27812501 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture plus fluoxetine
Number of subjects: 46
Study 24647680 — intervention group
Group type: EXPERIMENTAL
Intervention: DECIDE intervention (three training sessions delivered by a care manager)
Number of subjects: 647
Study 24647680 — intervention group
Group type: COMPARATOR
Intervention: Control group (brochure on management of behavioral health)
Number of subjects: 647
Study 22913571 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) intervention including prescribing indicator feedback reports and small group discussions with peers and a trained facilitator.
Number of subjects: 0
Study 22913571 — intervention group
Group type: COMPARATOR
Intervention: Control group (waitlisted to receive the intervention 6 months later).
Number of subjects: 0
Study 20200268 — intervention group
Group type: EXPERIMENTAL
Intervention: Sergliflozin etabonate 500 mg
Number of subjects: 18
Study 20200268 — intervention group
Group type: EXPERIMENTAL
Intervention: Sergliflozin etabonate 1000 mg
Number of subjects: 18
Study 20200268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 20200268 — intervention group
Group type: EXPERIMENTAL
Intervention: Sergliflozin etabonate 500 or 1000 mg
Number of subjects: 18
Study 17944916 — intervention group
Group type: EXPERIMENTAL
Intervention: Revealed high‐risk HPV test result in addition to cervical cytology
Number of subjects: 0
Study 17944916 — intervention group
Group type: COMPARATOR
Intervention: Concealed high‐risk HPV test result
Number of subjects: 0
Study 15657326 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg/d of conjugated equine estrogens (CEE)
Number of subjects: 22579
Study 15657326 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin (E + P), given as CEE plus 2.5 mg/d of medroxyprogesterone acetate
Number of subjects: 22579
Study 15657326 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin (E + P)
Number of subjects: 22579
Study 12870569 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (600 mg/day)
Number of subjects: 269